Biomarin Pharmaceutical Inc (BMRN)vsRevolution Medicines Inc (RVMD)
BMRN
Biomarin Pharmaceutical Inc
$65.68
+0.26%
HEALTHCARE · Cap: $12.51B
RVMD
Revolution Medicines Inc
$203.77
+0.21%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Biomarin Pharmaceutical Inc generates 459012% more annual revenue ($3.41B vs $742,000). BMRN leads profitability with a 2.1% profit margin vs 0.0%. BMRN earns a higher WallStSmart Score of 56/100 (C).
BMRN
Buy56
out of 100
Grade: C
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+66.4%
Fair Value
$179.58
Current Price
$65.68
$113.90 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Strong operational efficiency at 21.2%
19.9% revenue growth
Conservative balance sheet, low leverage
Areas to Watch
ROE of 1.1% — below average capital efficiency
2.1% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 16.8x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : BMRN
The strongest argument for BMRN centers on PEG Ratio, Altman Z-Score, Price/Book. Revenue growth of 19.9% demonstrates continued momentum. PEG of 0.39 suggests the stock is reasonably priced for its growth.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : BMRN
The primary concerns for BMRN are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 174.7x leaves little room for execution misses. Thin 2.1% margins leave little buffer for downturns.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
BMRN profiles as a growth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
BMRN is growing revenue faster at 19.9% — sustainability is the question.
BMRN generates stronger free cash flow (139M), providing more financial flexibility.
Bottom Line
BMRN scores higher overall (56/100 vs 24/100) and 19.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biomarin Pharmaceutical Inc
HEALTHCARE · BIOTECHNOLOGY · USA
BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?